ES2136599T3 - Tratamiento de las heridas utilizando peptidos biologicamente activos. - Google Patents

Tratamiento de las heridas utilizando peptidos biologicamente activos.

Info

Publication number
ES2136599T3
ES2136599T3 ES91902831T ES91902831T ES2136599T3 ES 2136599 T3 ES2136599 T3 ES 2136599T3 ES 91902831 T ES91902831 T ES 91902831T ES 91902831 T ES91902831 T ES 91902831T ES 2136599 T3 ES2136599 T3 ES 2136599T3
Authority
ES
Spain
Prior art keywords
biologically active
wound treatment
active peptides
wound
host
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91902831T
Other languages
English (en)
Inventor
Barry Berkowitz
Leonard S Jacob
Michael Zasloff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Magainin Pharmaceuticals Inc
Original Assignee
Magainin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magainin Pharmaceuticals Inc filed Critical Magainin Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2136599T3 publication Critical patent/ES2136599T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751Bactericidal/permeability-increasing protein [BPI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742Bactericidal/Permeability-increasing protein [BPI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

TRATAMIENTO DE HERIDAS QUE EMPLEA PEPTIDOS BIOLOGICAMENTE ACTIVOS. UN PROCESO PARA EL TRATAMIENTO DE UNA HERIDA EN UN HUESPED QUE COMPRENDE LA ADMINISTRACION AL HUESPED QUE TIENE UNA HERIDA DE, AL MENOS, UN PEPTIDO ANFIFILICO BIOLOGICAMENTE ACTIVO. EL PEPTIDO ES UN PEPTIDO CON FORMACION DE CANALES DE IONES Y SE ADMINISTRA EN UNA CANTIDAD EFICAZ PARA EL TRATAMIENTO DE LA HERIDA EN UN HUESPED.
ES91902831T 1989-12-18 1990-12-12 Tratamiento de las heridas utilizando peptidos biologicamente activos. Expired - Lifetime ES2136599T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/451,777 US5045531A (en) 1989-12-18 1989-12-18 Wound treatment employing biologically active ion channel forming peptides and proteins
PCT/US1990/007440 WO1991008758A1 (en) 1989-12-18 1990-12-12 Wound treatment employing biologically active peptides

Publications (1)

Publication Number Publication Date
ES2136599T3 true ES2136599T3 (es) 1999-12-01

Family

ID=23793638

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91902831T Expired - Lifetime ES2136599T3 (es) 1989-12-18 1990-12-12 Tratamiento de las heridas utilizando peptidos biologicamente activos.

Country Status (10)

Country Link
US (2) US5045531A (es)
EP (1) EP0505497B1 (es)
JP (1) JPH05504566A (es)
AT (1) ATE181835T1 (es)
CA (1) CA2032059C (es)
DE (1) DE69033200T2 (es)
DK (1) DK0505497T3 (es)
ES (1) ES2136599T3 (es)
GR (1) GR3031459T3 (es)
WO (1) WO1991008758A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327311C (en) * 1987-07-06 1994-03-01 Jesse M. Jaynes Therapeutic antimicrobial polypeptides, their use and methods for preparation
US5861478A (en) * 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
WO1989000194A1 (en) 1987-07-06 1989-01-12 Louisiana State University Agricultural And Mechan Inhibition of eucaryotic pathogens and neoplasms and stimulation of fibroblasts and lymphocytes with lytic peptides
US5912231A (en) * 1989-07-07 1999-06-15 Scripps Clinic And Research Foundation Substitution analogues of magainin peptides
US5242902A (en) * 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
NZ237202A (en) * 1990-02-23 1994-01-26 Bristol Myers Squibb Co Composition containing beta-lactam antibiotic and cationic oligopeptide
AU648140B2 (en) * 1991-02-01 1994-04-14 Virtual Drug Development, Inc. Reverse antimicrobial peptides and antimicrobial compositions
WO1993001723A1 (en) * 1991-07-25 1993-02-04 Magainin Pharmaceuticals, Inc. Prophylaxis and treatment of adverse oral conditions with biologically active peptides
US5656456A (en) * 1992-07-13 1997-08-12 Bionebraska, Inc. Chemical method for selective modification of the N- and/or C-terminal amino acid α-carbon reactive group of a recombinant polypeptide or a portion thereof
ATE225801T1 (de) * 1992-07-13 2002-10-15 Bionebraska Inc Verfahren zur modifizierung rekombinanter polypeptide
US5593866A (en) * 1992-08-21 1997-01-14 The University Of British Columbia Cationic peptides and method for production
AU6251594A (en) * 1993-02-26 1994-09-14 Magainin Pharmaceuticals, Inc. Treatment of cancerous growths with biologically active peptides and protease inhibitors
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5561107A (en) * 1993-06-04 1996-10-01 Demeter Biotechnologies, Ltd. Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides
US5968904A (en) * 1993-06-04 1999-10-19 Demegen, Inc. Modified arginine containing lytic peptides and method of making the same by glyoxylation
US5856178A (en) * 1993-08-30 1999-01-05 Utah State University DNA cassettes for expression of lytic peptides in mammalian cells and transgenic organisms containing same
KR960704524A (ko) * 1993-10-25 1996-10-09 카롤 질레스피 디피신을 함유한 리포좀(liposomal defensins)
AU1086595A (en) 1993-11-08 1995-05-29 Demeter Biotechnologies, Ltd. Methylated lysine-rich lytic peptides and method of making same by reductive alkylation
US6057291A (en) 1995-06-02 2000-05-02 University Of British Columbia Antimicrobial cationic peptides
FR2735983B1 (fr) 1995-06-29 1997-12-05 Centre Nat Rech Scient Peptide permettant de modifier l'activite du systeme immunitaire humain ou animal
US6191254B1 (en) 1995-08-23 2001-02-20 University Of British Columbia Antimicrobial cationic peptides
US6077826A (en) * 1996-01-25 2000-06-20 Kansas State University Research Foundation Synthetic macromolecular channel assembly for transport of chloride ions through epithelium useful in treating cystic fibrosis
JP4048565B2 (ja) * 1996-04-23 2008-02-20 東レ株式会社 「抗ピロリ菌剤」
DE10051983A1 (de) * 2000-10-20 2002-06-13 Beate Kehrel Inhibierung der pathogenen Wirkung oxidierter Proteine
WO2005094423A2 (en) * 2004-02-26 2005-10-13 President And Fellows Of Harvard College Selective inhibition of proteasomes of tuberculosis and other bacteria
WO2009070564A2 (en) * 2007-11-27 2009-06-04 Macrochem Corporation Compositions and methods for prevention of infection in transcutaneous osseointegrated implants
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507230A (en) * 1982-05-12 1985-03-26 Research Corporation Peptide synthesis reagents and method of use
US4863899A (en) * 1983-05-09 1989-09-05 Todaro George J Biologically active polypeptides
US4734399A (en) * 1985-08-06 1988-03-29 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4810777A (en) * 1987-03-04 1989-03-07 The United States Of America As Represented By The Department Of Health And Human Services Antimicrobial compounds
DE3852636T2 (de) * 1987-12-24 1995-05-04 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2).
US4962277A (en) * 1988-12-09 1990-10-09 Scripps Clinic And Research Foundation Deletion analogues of magainin peptides
US5073542A (en) * 1989-06-07 1991-12-17 Magainin Sciences Inc. CPF peptide compositions and their use in inhibiting growth of target cells or a virus

Also Published As

Publication number Publication date
EP0505497A1 (en) 1992-09-30
DE69033200D1 (de) 1999-08-12
CA2032059A1 (en) 1991-06-19
EP0505497B1 (en) 1999-07-07
WO1991008758A1 (en) 1991-06-27
CA2032059C (en) 2003-02-25
EP0505497A4 (en) 1993-09-08
DK0505497T3 (da) 1999-11-22
US5045531A (en) 1991-09-03
DE69033200T2 (de) 2000-02-24
GR3031459T3 (en) 2000-01-31
JPH05504566A (ja) 1993-07-15
USRE35492E (en) 1997-04-08
ATE181835T1 (de) 1999-07-15

Similar Documents

Publication Publication Date Title
ES2136599T3 (es) Tratamiento de las heridas utilizando peptidos biologicamente activos.
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
ES2196640T3 (es) Dispositivo terapeutico transdermico con capsaicina y analogos de capsaicina.
SE8501050D0 (sv) Biologically active fragments of human antihemophilic factor and method for preparation thereof
GEP20002146B (en) Therapeutic Peptide Derivatives
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
DE69132688D1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE306931T1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
DE69625682T2 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE103804T1 (de) Pharmazeutische praeparate.
DK403384D0 (da) Enteralt effektivt, biologisk aktivt peptid- eller proteinmiddel ogfremgangsmaader til fremstilling deraf
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
ATE107170T1 (de) Zusammensetzung und behandelung mittels biologisch aktiven peptiden und bestimmten anionen.
DE69739482D1 (de) Therapeutische formulierungen, die schlangen- und/oder insektengift enthalten, zur prophylaxe und therapie von neoplasmen
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
FR2549835B1 (fr) Acides peneme-carboxyliques, leur preparation et leur utilisation therapeutique, notamment en tant qu'agents antibacteriens
BR9708037A (pt) Método para o tratamento de abuso de substância
GEP20012377B (en) Use of Trophoblastic Beta-1 Glycoprotein for Treating Auto-Immune Diseases and Method of Treatment These Diseases
RU94044795A (ru) Способ лечения невралгии тройничного нерва
NO911470L (no) Sammensetning og behandling med biologisk aktive peptiderog visse anioner.
RU93058154A (ru) Способ лечения ранних приобретенных форм сифилиса
RU92016096A (ru) Массажное устройство
GR1000913B (el) Συνθεση & θεραπεια με βιολογικως δραστικα πεπτιδια & ορισμενα ανιοντα
RU94045317A (ru) Способ лечения вилюйского энцефаломиелита

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 505497

Country of ref document: ES